跳至主要内容
临床试验/NCT00925678
NCT00925678已完成1 期

A Double-blind, Placebo-controlled, Randomised Study to Investigate the Tolerability, Safety, Pharmacokinetics and Pharmacodynamics of Single Ascending Doses of DSP-3025 Administered Intranasally to Healthy Male Volunteers and Seasonal Allergic Rhinitis Male Patients Out of Season

Sumitomo Pharma Co., Ltd.1 个研究点 分布在 1 个国家目标入组 72 人开始时间: 2009年6月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
1 期
状态
已完成
入组人数
72
试验地点
1
主要终点
Incidence/nature of adverse events, 12-lead ECG, pulse, BP, body temperature, spirometry

研究概览

简要总结

Investigate safety/tolerability after a single dose intranasal administration of DSP-3025 comparator placebo to healthy male volunteers and seasonal allergic rhinitis male patients out of season.

研究设计

研究类型
Interventional
分配方式
Randomized
盲法
Double

入排标准

年龄范围
20 Years 至 39 Years(Adult)
性别
Male
接受健康志愿者

入选标准

  • Body mass index (BMI) between 18.5 and 25 kg/ m2 and a weight between 50 and 80 kg
  • No clinically relevant abnormal findings
  • History of cedar and/or Japanese cypress pollen induced seasonal allergic rhinitis for at least the previous 2 years (only Allergic rhinitis)

排除标准

  • Acute illness which requires medical intervention
  • Definite or suspected personal history of adverse drug reactions or drug hypersensitivity
  • Clinical relevant disease or disorder (past or present)
  • A history of asthma

研究组 & 干预措施

1

Experimental

干预措施: DSP-3025 (Drug)

2

Placebo Comparator

干预措施: Placebo (Drug)

结局指标

主要结局

Incidence/nature of adverse events, 12-lead ECG, pulse, BP, body temperature, spirometry

次要结局

  • Pharmacokinetics
  • Clinical chemistry, haematology, urinalysis
  • Nasal symptoms and peak nasal inspiratory flow
  • Biomarkers nasal lavage and blood

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验